CY1123552T1 - Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas - Google Patents
Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonasInfo
- Publication number
- CY1123552T1 CY1123552T1 CY20201100949T CY201100949T CY1123552T1 CY 1123552 T1 CY1123552 T1 CY 1123552T1 CY 20201100949 T CY20201100949 T CY 20201100949T CY 201100949 T CY201100949 T CY 201100949T CY 1123552 T1 CY1123552 T1 CY 1123552T1
- Authority
- CY
- Cyprus
- Prior art keywords
- psl
- binding molecules
- pcrv
- combination therapies
- pseudomonas
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 208000032536 Pseudomonas Infections Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Η αποκάλυψη αυτή αναφέρεται σε θεραπείες συνδυασμού που περιλαμβάνουν μόρια πρόσδεσης Psl και PcrV αντι-Ρseudomonas και σχετικές συνθέσεις, για χρήση στην πρόληψη και θεραπευτική αγωγή λοίμωξης από Pseudomonas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161556645P | 2011-11-07 | 2011-11-07 | |
US201261625299P | 2012-04-17 | 2012-04-17 | |
US201261697585P | 2012-09-06 | 2012-09-06 | |
PCT/US2012/063722 WO2013070615A1 (en) | 2011-11-07 | 2012-11-06 | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123552T1 true CY1123552T1 (el) | 2022-03-24 |
Family
ID=48290482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100949T CY1123552T1 (el) | 2011-11-07 | 2020-10-08 | Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas |
Country Status (22)
Country | Link |
---|---|
US (3) | US10597439B2 (el) |
EP (1) | EP2776065B1 (el) |
JP (1) | JP6182152B2 (el) |
KR (1) | KR102184343B1 (el) |
CN (1) | CN104136042B (el) |
AU (3) | AU2012336028A1 (el) |
BR (1) | BR112014011028B1 (el) |
CA (2) | CA2854817C (el) |
CY (1) | CY1123552T1 (el) |
DK (1) | DK2776065T3 (el) |
ES (1) | ES2859323T3 (el) |
HK (1) | HK1201453A1 (el) |
HR (1) | HRP20201370T1 (el) |
HU (1) | HUE050985T2 (el) |
LT (1) | LT2776065T (el) |
MX (1) | MX2014005566A (el) |
PL (1) | PL2776065T3 (el) |
PT (1) | PT2776065T (el) |
RS (1) | RS60920B1 (el) |
RU (1) | RU2687588C2 (el) |
SI (1) | SI2776065T1 (el) |
WO (1) | WO2013070615A1 (el) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2718320T (lt) | 2011-06-10 | 2018-04-10 | Medimmune Limited | Anti-pseodomonas psl surišančios molekulės ir jų panaudojimas |
MX2014005566A (es) | 2011-11-07 | 2014-10-14 | Medimmune Llc | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. |
US10072098B2 (en) | 2012-03-02 | 2018-09-11 | Ablynx N.V. | Pseudomonas aeruginosa PCRV binding single variable domain antibodies |
MX2015005719A (es) * | 2012-11-06 | 2016-01-12 | Medimmune Llc | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. |
JP2016524606A (ja) | 2013-05-14 | 2016-08-18 | メディミューン,エルエルシー | 緑膿菌(Pseudomonasaeruginosa)のPslエキソ多糖の合成オリゴ糖サブユニットおよびその使用 |
US20170183397A1 (en) * | 2014-05-05 | 2017-06-29 | Medimmune, Llc | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
MX2017014002A (es) | 2015-05-01 | 2018-08-01 | Inhibrx Lp | Moléculas de direccionamiento del sistema de secreción tipo iii . |
AU2016313653A1 (en) * | 2015-08-24 | 2018-04-12 | Medimmune, Llc | MrkA polypeptides, antibodies, and uses thereof |
SG10201913100WA (en) | 2015-11-30 | 2020-03-30 | Medimmune Ltd | Method for preventing or treating nosocomial pneumonia |
SG10202011016WA (en) * | 2016-05-05 | 2020-12-30 | Univ Pennsylvania | Dna antibody constructs for use against pseudomonas aeruginosa |
MX2021015156A (es) | 2019-06-11 | 2022-01-18 | Regeneron Pharma | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos. |
JP7478807B2 (ja) * | 2019-07-09 | 2024-05-07 | 北京三▲諾▼佳邑生物技▲術▼有限▲責▼任公司 | シュードモナス菌PcrVを特異的に認識する抗体及びその使用 |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
WO2021244421A1 (en) * | 2020-06-01 | 2021-12-09 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing pseudomonas pcrv and uses thereof |
KR20230065262A (ko) * | 2020-08-07 | 2023-05-11 | 베이징 솔로바이오 진테크놀로지 컴퍼니 리미티드 | 슈도모나스 psl을 특이적으로 인식하는 항체 및 이의 용도 |
FR3114970B1 (fr) * | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
EP4247846A4 (en) * | 2020-11-18 | 2024-07-03 | Beijing Solobio Genetechnology Co Ltd | COMBINATIONS OF ANTIBODIES AND BISPECIFIC ANTIBODIES WITH ANTIGEN-BINDING SPECIFIC RECOGNITION OF PSEUDOMONAS PCRV AND PSL |
WO2023141611A2 (en) * | 2022-01-21 | 2023-07-27 | Lyvgen Biopharma Holdings Limited | Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation |
TW202417478A (zh) | 2022-06-29 | 2024-05-01 | 瑞典商阿斯特捷利康公司 | 用於治療支氣管擴張的抗PcrV和Psl雙特異性藥物 |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
DE3685700T2 (de) | 1985-03-11 | 1993-03-11 | Teijin Ltd | E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom. |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
AU8619698A (en) | 1997-07-25 | 1999-02-16 | Ban C. H. Tsui | Devices, systems and methods for determining proper placement of epidural catheters |
SI1071752T1 (en) | 1998-04-21 | 2003-12-31 | Micromet Ag | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
ATE539349T1 (de) | 1998-11-25 | 2012-01-15 | Mcw Res Found Inc | Verfahren zur diagnose einer pseudomonas aeruginosa infektion |
EP1340088B1 (en) | 2000-11-17 | 2007-01-17 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン,エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
ES2275840T3 (es) * | 2001-01-26 | 2007-06-16 | Mcw Research Foundation, Inc. | Metodo y composiciones para inmunizar con el antigeno v de pseudomonas. |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
US20020146753A1 (en) * | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
US7119172B2 (en) | 2001-05-21 | 2006-10-10 | The Brigham And Women's Hospital, Inc. | P. aeruginosa mucoid exopolysaccharide specific binding peptides |
US20030232387A1 (en) * | 2002-06-14 | 2003-12-18 | Millennium Pharmaceuticals, Inc. | Antibodies that bind alphaE integrin |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
BRPI0615026A8 (pt) | 2005-08-19 | 2018-03-06 | Abbott Lab | imunoglobulina de domínio variável duplo e seus usos |
EP2044118A2 (en) * | 2006-06-13 | 2009-04-08 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
JP2008133206A (ja) * | 2006-11-28 | 2008-06-12 | Yokohama City Univ | 緑膿菌に対して感染防御能を誘導できる医薬組成物 |
US7553936B2 (en) * | 2006-12-04 | 2009-06-30 | The United States of America as represented by Secretary Department of Health and Human Services | Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions |
CA2672965C (en) * | 2006-12-19 | 2018-02-06 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
CN101910197B (zh) * | 2007-11-30 | 2014-09-24 | 卡罗拜奥斯制药公司 | 针对铜绿假单胞菌pcrv抗原的抗体 |
EP2599792A1 (en) * | 2008-01-10 | 2013-06-05 | Shionogi&Co., Ltd. | Antibody directed against PcrV |
WO2009092011A1 (en) | 2008-01-18 | 2009-07-23 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
MX2011005672A (es) | 2008-11-28 | 2011-06-20 | Abbott Lab | Composiciones de anticuerpo estables y metodos para estabilizar a las mismas. |
JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US9061811B2 (en) * | 2008-12-31 | 2015-06-23 | Lothar Egersdoerfer | Venting device |
US20100272736A1 (en) * | 2009-02-04 | 2010-10-28 | Kalobios Pharmaceuticals, Inc. | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
SG174225A1 (en) * | 2009-03-11 | 2011-10-28 | Shionogi & Co | Humanized pcrv antibody having anti-pseudomonal activity |
US9096659B2 (en) * | 2009-03-18 | 2015-08-04 | Wake Forest University Health Sciences | Flagellin fusion proteins and use thereof to induce immune responses against Pseudomonas aeruginosa |
CA2755336C (en) | 2009-03-20 | 2015-07-14 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
EP2417157A1 (en) | 2009-04-09 | 2012-02-15 | Kenta Biotech AG | Human monoclonal antibody specific for lipolysaccarides (lps) of serotype lats 01 of pseudomonas aeruginosa |
JP5918129B2 (ja) | 2009-06-22 | 2016-05-18 | メディミューン,エルエルシー | 部位特異的共役のための操作されたFc領域 |
JP2013515079A (ja) | 2009-12-22 | 2013-05-02 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 低レベルの病原性シュードモナス・エルギノーサ(Pseudomonasaeruginosa)感染症を有する患者のスタフィロコッカス(Staphylococcus)感染症を治療する方法 |
ES2709065T7 (es) * | 2011-02-08 | 2021-12-09 | Medimmune Llc | Anticuerpos que se unen específicamente a la toxina alfa de Staphylococcus aureus y métodos de uso |
WO2012145626A1 (en) | 2011-04-22 | 2012-10-26 | Ancora Pharmaceuticals Inc. | Synthetic oligosaccharides for staphylococcus vaccine |
LT2718320T (lt) * | 2011-06-10 | 2018-04-10 | Medimmune Limited | Anti-pseodomonas psl surišančios molekulės ir jų panaudojimas |
MX2014005566A (es) * | 2011-11-07 | 2014-10-14 | Medimmune Llc | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. |
EP2776061B1 (en) * | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
US10072098B2 (en) * | 2012-03-02 | 2018-09-11 | Ablynx N.V. | Pseudomonas aeruginosa PCRV binding single variable domain antibodies |
SG10201703677VA (en) * | 2012-11-06 | 2017-06-29 | Medimmune Llc | Methods of treating s. aureus-associated diseases |
MX2015005719A (es) * | 2012-11-06 | 2016-01-12 | Medimmune Llc | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. |
RU2698131C2 (ru) * | 2012-11-06 | 2019-08-22 | МЕДИММЬЮН, ЭлЭлСи | Антитела к поверхностным детерминантам s. aureus |
JP2016524606A (ja) | 2013-05-14 | 2016-08-18 | メディミューン,エルエルシー | 緑膿菌(Pseudomonasaeruginosa)のPslエキソ多糖の合成オリゴ糖サブユニットおよびその使用 |
US20170183397A1 (en) * | 2014-05-05 | 2017-06-29 | Medimmune, Llc | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
SG10201913100WA (en) * | 2015-11-30 | 2020-03-30 | Medimmune Ltd | Method for preventing or treating nosocomial pneumonia |
SG10202011016WA (en) * | 2016-05-05 | 2020-12-30 | Univ Pennsylvania | Dna antibody constructs for use against pseudomonas aeruginosa |
MX2021015156A (es) * | 2019-06-11 | 2022-01-18 | Regeneron Pharma | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos. |
-
2012
- 2012-11-06 MX MX2014005566A patent/MX2014005566A/es active IP Right Grant
- 2012-11-06 PT PT128474798T patent/PT2776065T/pt unknown
- 2012-11-06 RS RS20201211A patent/RS60920B1/sr unknown
- 2012-11-06 LT LTEP12847479.8T patent/LT2776065T/lt unknown
- 2012-11-06 PL PL12847479T patent/PL2776065T3/pl unknown
- 2012-11-06 EP EP12847479.8A patent/EP2776065B1/en active Active
- 2012-11-06 DK DK12847479.8T patent/DK2776065T3/da active
- 2012-11-06 US US14/356,500 patent/US10597439B2/en active Active
- 2012-11-06 CA CA2854817A patent/CA2854817C/en active Active
- 2012-11-06 CN CN201280054651.8A patent/CN104136042B/zh active Active
- 2012-11-06 JP JP2014540196A patent/JP6182152B2/ja active Active
- 2012-11-06 AU AU2012336028A patent/AU2012336028A1/en not_active Abandoned
- 2012-11-06 SI SI201231834T patent/SI2776065T1/sl unknown
- 2012-11-06 ES ES12847479T patent/ES2859323T3/es active Active
- 2012-11-06 HU HUE12847479A patent/HUE050985T2/hu unknown
- 2012-11-06 BR BR112014011028-0A patent/BR112014011028B1/pt active IP Right Grant
- 2012-11-06 RU RU2014122990A patent/RU2687588C2/ru active
- 2012-11-06 KR KR1020147015274A patent/KR102184343B1/ko active IP Right Grant
- 2012-11-06 CA CA3161431A patent/CA3161431A1/en active Pending
- 2012-11-06 WO PCT/US2012/063722 patent/WO2013070615A1/en active Application Filing
-
2015
- 2015-02-27 HK HK15101962.5A patent/HK1201453A1/xx unknown
-
2017
- 2017-08-25 AU AU2017219081A patent/AU2017219081B9/en active Active
-
2019
- 2019-09-05 AU AU2019226205A patent/AU2019226205A1/en not_active Abandoned
-
2020
- 2020-02-13 US US16/789,790 patent/US11203633B2/en active Active
- 2020-08-28 HR HRP20201370TT patent/HRP20201370T1/hr unknown
- 2020-10-08 CY CY20201100949T patent/CY1123552T1/el unknown
-
2021
- 2021-11-15 US US17/454,837 patent/US20220177554A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123552T1 (el) | Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas | |
CY1120557T1 (el) | Μορια δεσμευσης anti-pseudomonas psl και χρησεις αυτων | |
CY1122278T1 (el) | Αντι il-36r αντισωματα | |
CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
CY1121862T1 (el) | Αντισωματα anti-phf-tau και χρησεις αυτων | |
CY1118680T1 (el) | Φαρμακευτικη συνθεση | |
CY1123145T1 (el) | Anti-cd40 αντισωματα | |
CY1117678T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
CY1118014T1 (el) | Aνti-il-23 αντισωματα | |
BR112015010240A2 (pt) | Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas | |
EA201391507A1 (ru) | АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ | |
CY1118885T1 (el) | Συνθετικες πεπτιδογλυκανες που δεσμευουν υαλουρονικο οξυ, παρασκευη, και μεθοδοι χρησης | |
CY1123490T1 (el) | Συνθεσεις που προερχονται απο χιτοζανη | |
CY1116578T1 (el) | Αναστολεις της bromodomain και χρησεις αυτων | |
EA201390929A1 (ru) | Антитела к pcsk9 и способы их применения | |
EA202193044A2 (ru) | Способы лечения таупатии | |
EA201390274A1 (ru) | Борсодержащие малые молекулы | |
EA201390145A1 (ru) | Конъюгаты, частицы, композиции и связанные с ними способы | |
CY1121167T1 (el) | Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων | |
EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
EA201590174A1 (ru) | Иммуноконъюгаты, содержащие анти-cd22 антитела | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
EA201391248A1 (ru) | Биспецифические связывающие агенты | |
EA201490922A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 |